Viewing nowValsaract Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
JW Pharmaceutical Corp.

MFDS item code 200809208 · Notified 2008.09.03 · Insurance code 644912380
Treatment of essential hypertension and heart failure; reduction in the risk of death after myocardial infarction
This medication is used to treat essential hypertension and is also effective for heart failure patients who are intolerant to ACE inhibitors. Additionally, it helps reduce the risk of mortality in patients with left ventricular dysfunction following myocardial infarction. The drug alleviates symptoms of heart failure and improves heart function, contributing to the patient's quality of life. In summary, it is used for the treatment of essential hypertension and heart failure, as well as for reducing the risk of mortality after myocardial infarction.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during a meal or between meals. It is recommended to take the medicine at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (aged 75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose as tolerated by the patient to 40 mg, 80 mg, and 160 mg per dose, administered twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, it is preferable not to exceed a daily dose of 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Individuals with hypersensitivity to this drug, pregnant or nursing women, and those with severe liver or kidney impairment should not take this medication. Elderly patients, those with hyperkalemia, and patients with mild to moderate liver impairment should be particularly cautious when taking this medication, as blood pressure may drop rapidly; thus, starting with a low dose and gradually increasing is recommended for safety. During the use of this medication, side effects such as dizziness, headache, fatigue, cough, and diarrhea may occur. In severe cases, hypotension, renal function anomalies, or hyperkalemia can develop, so any symptoms should be discussed with medical personnel immediately. This medication can interact with other antihypertensive medications, diuretics, and potassium supplements; therefore, it is essential to inform the doctor of any current medications. It is advised that pregnant or nursing women do not take this medication, and if it is absolutely necessary to take it, breastfeeding should be discontinued. In the case of an overdose, severe hypotension and decreased consciousness can occur, so an immediate visit to the hospital for appropriate treatment is necessary. Safety and efficacy in children and adolescents have not been sufficiently established, so its use is not recommended. This medication should be kept out of the reach of children, and transferring it to other containers is not advisable as it may compromise the quality.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air and moisture from entering, and kept in a cool place below 30 degrees Celsius. This will help maintain the drug's effectiveness and prevent degradation.
Light red circular film-coated tablet
30 tablets (6 tablets/PTPX5)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
JW Pharmaceutical Corp.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.